Bone Marrow Transplantation News

A prognostic score based on the concentration of biomarkers guided risk-adapted therapy at the onset of graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, according to study results.

Improved surveillance and pre-emptive therapies may be required to better manage late-onset cytomegalovirus infections among pediatric bone marrow transplant patients.

Allogeneic hematopoietic stem cell transplant appears to be safe and effective for pediatric patients with mevalonate kinase deficiency who respond inadequately to anticytokine drugs, according to a recent case report.

High levels of the biomarker suppressor of tumorigenicity 2 at 28 days post-cord blood transplantation independently predicted acute graft-versus-host disease, according to study results.

Researchers at the Universidade Federal do Rio de Janeiro in Brazil determined that active smoking was associated with invasive fusariosis among patients undergoing induction remission for acute myeloid leukemia or myelodysplasia.

In the June 10 issue of HemOnc Today, we launched a series of columns to discuss high-priority proposals that emerged from the 2014 Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium.

SAN FRANCISCO — A population of CD146+ and chemokine receptor 5-positive, Th17-prone T cells may serve as an early marker for patients who are at risk for graft-versus-host disease of the gastrointestinal tract, according to study results presented at the ASH Annual Meeting and Exposition.

SAN FRANCISCO — Autologous hematopoietic stem cell transplantation conferred favorable outcomes in patients with HIV-associated non-Hodgkin’s or Hodgkin’s lymphoma, according to study results presented here.

SAN FRANCISCO — Brentuximab vedotin safely and effectively stalled disease progression in patients with Hodgkin’s lymphoma when administered early after autologous hematopoietic stem cell transplantation, according to results of the phase 3 AETHERA study presented at the ASH Annual Meeting and Exposition.

Allogeneic transplantation induced sustained remissions in patients with multiple myeloma, with the greatest survival benefit observed among those who underwent transplantation as consolidation therapy, according to study results.